These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24733588)

  • 1. Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.
    Liu YH; Wang YR; Xiang Y; Zhou HD; Giunta B; Mañucat-Tan NB; Tan J; Zhou XF; Wang YJ
    Mol Neurobiol; 2015 Feb; 51(1):1-7. PubMed ID: 24733588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model.
    Jin WS; Shen LL; Bu XL; Zhang WW; Chen SH; Huang ZL; Xiong JX; Gao CY; Dong Z; He YN; Hu ZA; Zhou HD; Song W; Zhou XF; Wang YZ; Wang YJ
    Acta Neuropathol; 2017 Aug; 134(2):207-220. PubMed ID: 28477083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.
    Hallé M; Tribout-Jover P; Lanteigne AM; Boulais J; St-Jean JR; Jodoin R; Girouard MP; Constantin F; Migneault A; Renaud F; Didierlaurent AM; Mallett CP; Burkhart D; Pilorget A; Palmantier R; Larocque D
    J Immunol Methods; 2015 Sep; 424():64-79. PubMed ID: 26002154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
    Nitsch RM; Hock C
    Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified immunotherapies against Alzheimer's disease: toward safer and effective amyloid clearance.
    Wang YJ; Zhou HD; Zhou XF
    J Alzheimers Dis; 2010; 21(4):1065-75. PubMed ID: 21504118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer disease: the challenge of adverse effects.
    Liu YH; Giunta B; Zhou HD; Tan J; Wang YJ
    Nat Rev Neurol; 2012 Aug; 8(8):465-9. PubMed ID: 22751529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Alzheimer's disease.
    Steinitz M
    Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Paris F; Santamato A; D'Onofrio G; Logroscino G; Pilotto A; Solfrizzi V
    Curr Alzheimer Res; 2011 Dec; 8(8):808-17. PubMed ID: 21592055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.
    Roher AE; Maarouf CL; Daugs ID; Kokjohn TA; Hunter JM; Sabbagh MN; Beach TG
    J Alzheimers Dis; 2011; 24(2):315-25. PubMed ID: 21263194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development.
    Nath A; Hall E; Tuzova M; Dobbs M; Jons M; Anderson C; Woodward J; Guo Z; Fu W; Kryscio R; Wekstein D; Smith C; Markesbery WR; Mattson MP
    Neuromolecular Med; 2003; 3(1):29-39. PubMed ID: 12665674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.